(Hypertension. 1999;33:894-899.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Erythropoietin Depresses Nitric Oxide Synthase Expression by Human Endothelial Cells
From the Division of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, Calif.
Correspondence to Dr Nosratola D. Vaziri, Division of Nephrology and Hypertension, Department of Medicine, UCI Medical Center, 101 The City Dr, Orange, CA 92868. E-mail tabotten{at}uci.edu
Abstract—We have recently shown that erythropoietin (EPO)-induced hypertension is unrelated to the rise in hematocrit and is marked by elevated cytosolic [Ca+2] and nitric oxide (NO) resistance. The present study was done to determine the effect of EPO on NO production and endothelial NO synthase (eNOS) expression by endothelial cells. Human coronary artery endothelial cells were cultured to subconfluence and then were incubated for 24 hours in the presence of either EPO (0, 5, and 20 U/mL) alone or EPO plus the calcium channel blocker felodipine. The experiments were carried out with quiescent (0.5% FCS) and proliferating (5% FCS) cells. Total nitrate and nitrite, eNOS protein, DNA synthesis (thymidine incorporation), and cell proliferation (cell count) were determined. In addition, NO production in response to acetylcholine stimulation was tested. EPO resulted in a dose-dependent inhibition of basal and acetylcholine-stimulated NO production and eNOS protein expression and also led to a significant dose-dependent stimulation of DNA synthesis in endothelial cells. The inhibitory effects of EPO on NO production and eNOS expression were reversed by felodipine. Thus, EPO downregulates basal and acetylcholine-stimulated NO production, depresses eNOS expression, and stimulates proliferation in isolated human endothelial cells. The suppressive effects of EPO on NO production and on eNOS expression are reversed by calcium channel blockade.
Key Words: erythropoietin • endothelium • nitric oxide • endothelium-derived relaxing factor • hypertension • calcium channel blockers
This article has been cited by other articles:
 |
|
 |
|
  N. D. Vaziri and X. J. Zhou Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1082 - 1088. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Krapf and H. N. Hulter Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA) Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 470 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-G. Ryou, J. Sun, K. N. Oguayo, E. B. Manukhina, H. F. Downey, and R. T. Mallet Hypoxic Conditioning Suppresses Nitric Oxide Production upon Myocardial Reperfusion Experimental Biology and Medicine, June 1, 2008; 233(6): 766 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Desai, Y. Zhao, and J. S. Warren Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1513 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cherian, J. C. Goodman, and C. Robertson Neuroprotection with Erythropoietin Administration Following Controlled Cortical Impact Injury in Rats J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 789 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors Am J Physiol Renal Physiol, November 1, 2006; 291(5): F932 - F944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dong and L. P. Thompson Differential Expression of Endothelial Nitric Oxide Synthase in Coronary and Cardiac Tissue in Hypoxic Fetal Guinea Pig Hearts Reproductive Sciences, October 1, 2006; 13(7): 483 - 490. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Fandrey A cordial affair - erythropoietin and cardioprotection Cardiovasc Res, October 1, 2006; 72(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. R. Santhanam, L. A. Smith, K. A. Nath, and Z. S. Katusic In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H781 - H786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Xing, B. E.K. Klein, R. Klein, G. Jun, K. E. Lee, and S. K. Iyengar Genome-Wide Linkage Study of Retinal Vessel Diameters in the Beaver Dam Eye Study Hypertension, April 1, 2006; 47(4): 797 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. He, S. Yang, and L. Zhang Effects of Cocaine on Nitric Oxide Production in Bovine Coronary Artery Endothelial Cells J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 980 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Vaziri, Y. Ding, Z. Ni, and C. H. Barton Bradykinin Down-Regulates, Whereas Arginine Analogs Up-Regulates, Endothelial Nitric-Oxide Synthase Expression in Coronary Endothelial Cells J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 121 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Scalera, J. T. Kielstein, J. Martens-Lobenhoffer, S. C. Postel, M. Tager, and S. M. Bode-Boger Erythropoietin Increases Asymmetric Dimethylarginine in Endothelial Cells: Role of Dimethylarginine Dimethylaminohydrolase J. Am. Soc. Nephrol., April 1, 2005; 16(4): 892 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Beleslin-Cokic, V. P. Cokic, X. Yu, B. B. Weksler, A. N. Schechter, and C. T. Noguchi Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells Blood, October 1, 2004; 104(7): 2073 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J Smith, A. J Bleyer, W. C Little, and D. C Sane The cardiovascular effects of erythropoietin Cardiovasc Res, September 1, 2003; 59(3): 538 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Govers and T. J. Rabelink Cellular regulation of endothelial nitric oxide synthase Am J Physiol Renal Physiol, February 1, 2001; 280(2): F193 - F206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Walker, T. C. Resta, and L. D. Nelin Nitric oxide-dependent pulmonary vasodilation in polycythemic rats Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2382 - H2389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. T. Ruschitzka, R. H. Wenger, T. Stallmach, T. Quaschning, C. de Wit, K. Wagner, R. Labugger, M. Kelm, G. Noll, T. Rulicke, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin PNAS, October 10, 2000; 97(21): 11609 - 11613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ding, N. D. Vaziri, R. Coulson, V. S. Kamanna, and D. D. Roh Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression Am J Physiol Endocrinol Metab, July 1, 2000; 279(1): E11 - E17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ding and N. D. Vaziri Nifedipine and Diltiazem but Not Verapamil Up-Regulate Endothelial Nitric-Oxide Synthase Expression J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 606 - 609. [Abstract] [Full Text]
|
|